secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-06-12T23:59:59+00:00
Accession:  0001628280-23-021819
Event type: other
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin stockholders approve reverse stock split and elect directors at 2023 annual meeting
--------------------------------------------------------------------------------

- Elected Class III directors Boyd, Palekar, and Simpson with >17.6M shares for each.
- Approved reverse stock split at ratio 1:2 to 1:5, board to set exact ratio within one year.
- Approved officer exculpation amendment with 11.6M For vs 8.8M Against (excluding broker non-votes).
- Ratified Deloitte & Touche as auditor for FY2023 with 27.0M shares for.
- Non-binding advisory vote on executive compensation approved with 13.5M For vs 6.8M Against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023021819/0001628280-23-021819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023021819/nltx-20230608.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-021819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer